Details
Stereochemistry | ACHIRAL |
Molecular Formula | C18H18F3NO4 |
Molecular Weight | 369.335 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OCCOCCOC(=O)C1=C(NC2=CC=CC(=C2)C(F)(F)F)C=CC=C1
InChI
InChIKey=XILVEPYQJIOVNB-UHFFFAOYSA-N
InChI=1S/C18H18F3NO4/c19-18(20,21)13-4-3-5-14(12-13)22-16-7-2-1-6-15(16)17(24)26-11-10-25-9-8-23/h1-7,12,22-23H,8-11H2
DescriptionSources: http://www.drugbank.ca/drugs/DB08984Curator's Comment: Description was created based on several sources, including
http://www.mims.com/india/drug/info/etofenamate?mtype=generic
https://www.ncbi.nlm.nih.gov/pubmed/6983482
Sources: http://www.drugbank.ca/drugs/DB08984
Curator's Comment: Description was created based on several sources, including
http://www.mims.com/india/drug/info/etofenamate?mtype=generic
https://www.ncbi.nlm.nih.gov/pubmed/6983482
Etofenamate is a non-steroidal anti-inflammatory drug (NSAID) used for the treatment of joint and muscular pain.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL221 Sources: http://www.genome.jp/dbget-bin/www_bget?dr:D04102 |
|||
Target ID: CHEMBL230 Sources: http://www.genome.jp/dbget-bin/www_bget?dr:D04102 |
|||
Target ID: GO:0019372 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2883093 |
53.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Etofenamate Approved UseEtofenamate is an NSAID applied topically for the relief of pain and inflammation associated with musculoskeletal, joint and soft tissue disorders. |
|||
Palliative | Etofenamate Approved UseEtofenamate is an NSAID applied topically for the relief of pain and inflammation associated with musculoskeletal, joint and soft tissue disorders. |
Sample Use Guides
Intramuscular
Pain and inflammation
Adult: 1 g injected deeply in single doses.
Topical/Cutaneous
Pain and inflammation
Adult: Apply 5% or 10% conc topically on affected area.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2883093
PGE2 generation by rat peritoneal macrophages in MEM medium was dose-relatedly inhibited with etofenamate at the dosage range of 1 to 30 uM.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
M02AA06
Created by
admin on Sat Dec 16 17:53:29 GMT 2023 , Edited by admin on Sat Dec 16 17:53:29 GMT 2023
|
||
|
NCI_THESAURUS |
C257
Created by
admin on Sat Dec 16 17:53:29 GMT 2023 , Edited by admin on Sat Dec 16 17:53:29 GMT 2023
|
||
|
WHO-VATC |
QM02AA06
Created by
admin on Sat Dec 16 17:53:29 GMT 2023 , Edited by admin on Sat Dec 16 17:53:29 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C80545
Created by
admin on Sat Dec 16 17:53:29 GMT 2023 , Edited by admin on Sat Dec 16 17:53:29 GMT 2023
|
PRIMARY | |||
|
35375
Created by
admin on Sat Dec 16 17:53:29 GMT 2023 , Edited by admin on Sat Dec 16 17:53:29 GMT 2023
|
PRIMARY | |||
|
3359
Created by
admin on Sat Dec 16 17:53:29 GMT 2023 , Edited by admin on Sat Dec 16 17:53:29 GMT 2023
|
PRIMARY | |||
|
DB08984
Created by
admin on Sat Dec 16 17:53:29 GMT 2023 , Edited by admin on Sat Dec 16 17:53:29 GMT 2023
|
PRIMARY | |||
|
30544-47-9
Created by
admin on Sat Dec 16 17:53:29 GMT 2023 , Edited by admin on Sat Dec 16 17:53:29 GMT 2023
|
PRIMARY | |||
|
C015207
Created by
admin on Sat Dec 16 17:53:29 GMT 2023 , Edited by admin on Sat Dec 16 17:53:29 GMT 2023
|
PRIMARY | |||
|
3211
Created by
admin on Sat Dec 16 17:53:29 GMT 2023 , Edited by admin on Sat Dec 16 17:53:29 GMT 2023
|
PRIMARY | |||
|
Y-46
Created by
admin on Sat Dec 16 17:53:29 GMT 2023 , Edited by admin on Sat Dec 16 17:53:29 GMT 2023
|
PRIMARY | |||
|
24608
Created by
admin on Sat Dec 16 17:53:29 GMT 2023 , Edited by admin on Sat Dec 16 17:53:29 GMT 2023
|
PRIMARY | RxNorm | ||
|
KZF0XM66JC
Created by
admin on Sat Dec 16 17:53:29 GMT 2023 , Edited by admin on Sat Dec 16 17:53:29 GMT 2023
|
PRIMARY | |||
|
250-231-8
Created by
admin on Sat Dec 16 17:53:29 GMT 2023 , Edited by admin on Sat Dec 16 17:53:29 GMT 2023
|
PRIMARY | |||
|
ETOFENAMATE
Created by
admin on Sat Dec 16 17:53:29 GMT 2023 , Edited by admin on Sat Dec 16 17:53:29 GMT 2023
|
PRIMARY | |||
|
100000092609
Created by
admin on Sat Dec 16 17:53:29 GMT 2023 , Edited by admin on Sat Dec 16 17:53:29 GMT 2023
|
PRIMARY | |||
|
CHEMBL1451633
Created by
admin on Sat Dec 16 17:53:29 GMT 2023 , Edited by admin on Sat Dec 16 17:53:29 GMT 2023
|
PRIMARY | |||
|
m5191
Created by
admin on Sat Dec 16 17:53:29 GMT 2023 , Edited by admin on Sat Dec 16 17:53:29 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB07319MIG
Created by
admin on Sat Dec 16 17:53:29 GMT 2023 , Edited by admin on Sat Dec 16 17:53:29 GMT 2023
|
PRIMARY | |||
|
DTXSID2045448
Created by
admin on Sat Dec 16 17:53:29 GMT 2023 , Edited by admin on Sat Dec 16 17:53:29 GMT 2023
|
PRIMARY |
ACTIVE MOIETY